Literature DB >> 24656222

Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK.

Mark Speakman1, Roger Kirby, Scott Doyle, Chris Ioannou.   

Abstract

KEY MESSAGES: Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) can be bothersome and negatively impact on a patient's quality of life (QoL). As the prevalence of LUTS/BPH increases with age, the burden on the healthcare system and society may increase due to the ageing population. This review unifies literature on the burden of LUTS/BPH on patients and society, particularly in the UK. LUTS/BPH is associated with high personal and societal costs, both in direct medical costs and indirect losses in daily functioning, and through its negative impact on QoL for patients and partners. LUTS/BPH is often underdiagnosed and undertreated. Men should be encouraged to seek medical advice for this condition and should not accept it as part of ageing, while clinicians should be more active in the identification and treatment of LUTS/BPH. To assess the burden of illness and unmet need arising from lower urinary tract symptoms (LUTS) presumed secondary to benign prostatic hyperplasia (BPH) from an individual patient and societal perspective with a focus on the UK. Embase, PubMed, the World Health Organization, the Cochrane Database of Systematic Reviews and the York Centre for Reviews and Dissemination were searched to identify studies on the epidemiological, humanistic or economic burden of LUTS/BPH published in English between October 2001 and January 2013. Data were extracted and the quality of the studies was assessed for inclusion. UK data were reported; in the absence of UK data, European and USA data were provided. In all, 374 abstracts were identified, 104 full papers were assessed and 33 papers met the inclusion criteria and were included in the review. An additional paper was included in the review upon a revision in 2014. The papers show that LUTS are common in the UK, affecting ≈3% of men aged 45-49 years, rising to >30% in men aged ≥85 years. European and USA studies have reported the major impact of LUTS on quality of life of the patient and their partner. LUTS are associated with high personal and societal costs, both in direct medical costs and indirect losses in daily functioning. While treatment costs in the UK are relatively low compared with other countries, the burden on health services is still substantial. LUTS associated with BPH is a highly impactful condition that is often undertreated. LUTS/BPH have a major impact on men, their families, health services and society. Men with LUTS secondary to BPH should not simply accept their symptoms as part of ageing, but should be encouraged to consult their physicians if they have bothersome symptoms.
© 2014 The Authors. BJU International © 2014 BJU International.

Entities:  

Keywords:  BPH; LUTS; burden of illness; economics; epidemiology; quality of life

Mesh:

Year:  2014        PMID: 24656222     DOI: 10.1111/bju.12745

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  60 in total

1.  Critical reviews of 1470-nm laser vaporization on benign prostatic hyperplasia.

Authors:  Zhifeng Liu; Yongwei Zhao; Xingliang Wang; Mingshan Song; Benkang Shi
Journal:  Lasers Med Sci       Date:  2017-11-11       Impact factor: 3.161

2.  Cost of illness of medically treated benign prostatic hyperplasia in Hungary.

Authors:  Fanni Rencz; Ágnes Kovács; Valentin Brodszky; László Gulácsi; Zalán Németh; Gábor János Nagy; János Nagy; István Buzogány; Géza Böszörményi-Nagy; Attila Majoros; Péter Nyirády
Journal:  Int Urol Nephrol       Date:  2015-06-21       Impact factor: 2.370

3.  Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction.

Authors:  Valter Silva; Antonio Jose Grande; Maria S Peccin
Journal:  Cochrane Database Syst Rev       Date:  2019-04-06

4.  Effective management of male lower urinary tract symptoms in primary care.

Authors:  Jo Worthington; Jessica Frost; J Athene Lane; Luke A Robles; Jon Rees; Gordon Taylor; Marcus J Drake; Matthew Ridd
Journal:  Br J Gen Pract       Date:  2021-08-26       Impact factor: 6.302

5.  Urinary Amine Metabolomics Characterization with Custom 12-Plex Isobaric DiLeu Labeling.

Authors:  Pingli Wei; Ling Hao; Samuel Thomas; Amanda Rae Buchberger; Laura Steinke; Paul C Marker; William A Ricke; Lingjun Li
Journal:  J Am Soc Mass Spectrom       Date:  2020-08-04       Impact factor: 3.109

6.  Urinary Metabolomic and Proteomic Analyses in a Mouse Model of Prostatic Inflammation.

Authors:  Pingli Wei; Ling Hao; Fengfei Ma; Qing Yu; Amanda Rae Buchberger; Sanghee Lee; Wade Bushman; Lingjun Li
Journal:  Urine (Amst)       Date:  2020-05-27

7.  Using Search Trends to Analyze Web-Based Interest in Lower Urinary Tract Symptoms-Related Inquiries, Diagnoses, and Treatments in Mainland China: Infodemiology Study of Baidu Index Data.

Authors:  Shanzun Wei; Ming Ma; Changjing Wu; Botao Yu; Lisha Jiang; Xi Wen; Fudong Fu; Ming Shi
Journal:  J Med Internet Res       Date:  2021-07-06       Impact factor: 5.428

8.  Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction.

Authors:  Cameron Edwin Alexander; Malo Mf Scullion; Muhammad Imran Omar; Yuhong Yuan; Charalampos Mamoulakis; James Mo N'Dow; Changhao Chen; Thomas Bl Lam
Journal:  Cochrane Database Syst Rev       Date:  2019-12-03

Review 9.  The prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveys.

Authors:  Wenying Wang; Yuwen Guo; Daoxin Zhang; Ye Tian; Xiaonan Zhang
Journal:  Sci Rep       Date:  2015-08-26       Impact factor: 4.379

10.  Depression and Its Severity Are Strongly Associated with Both Storage and Voiding Lower Urinary Tract Symptoms Independently of Prostate Volume.

Authors:  Su-Min Jeong; Beomseok Suh; Soo Hyun Jang; Ho Seong Jin; Nakhyun Kim; Hyuktae Kwon; Belong Cho; Jin-Ho Park
Journal:  J Korean Med Sci       Date:  2015-10-16       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.